These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21045601)

  • 21. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
    Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
    Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
    Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highly active antiretroviral treatment for the prevention of HIV transmission.
    Granich R; Crowley S; Vitoria M; Lo YR; Souteyrand Y; Dye C; Gilks C; Guerma T; De Cock KM; Williams B
    J Int AIDS Soc; 2010 Jan; 13():1. PubMed ID: 20205768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.
    Celentano DD; Galai N; Sethi AK; Shah NG; Strathdee SA; Vlahov D; Gallant JE
    AIDS; 2001 Sep; 15(13):1707-15. PubMed ID: 11546947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV.
    Palombi L; Marazzi MC; Voetberg A; Magid NA
    AIDS; 2007 Jul; 21 Suppl 4():S65-71. PubMed ID: 17620755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of illicit drug use and substance abuse treatment on adherence to HAART.
    Hicks PL; Mulvey KP; Chander G; Fleishman JA; Josephs JS; Korthuis PT; Hellinger J; Gaist P; Gebo KA;
    AIDS Care; 2007 Oct; 19(9):1134-40. PubMed ID: 18058397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy.
    Floris-Moore M; Lo Y; Klein RS; Budner N; Gourevitch MN; Moskaleva G; Schoenbaum EE
    J Acquir Immune Defic Syndr; 2003 Nov; 34(3):331-7. PubMed ID: 14600580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outpatient patterns of care and longitudinal intensity of antiretroviral therapy for HIV-infected drug users.
    Laine C; Hauck WW; Turner BJ
    Med Care; 2002 Oct; 40(10):976-95. PubMed ID: 12395030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women.
    McCabe CJ; Goldie SJ; Fisman DN
    PLoS One; 2010 Apr; 5(4):e10154. PubMed ID: 20405011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection.
    Lucas GM; Cheever LW; Chaisson RE; Moore RD
    J Acquir Immune Defic Syndr; 2001 Jul; 27(3):251-9. PubMed ID: 11464144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV.
    Carrico AW
    Life Sci; 2011 May; 88(21-22):940-7. PubMed ID: 20934437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared.
    Keiser O; Orrell C; Egger M; Wood R; Brinkhof MW; Furrer H; van Cutsem G; Ledergerber B; Boulle A;
    PLoS Med; 2008 Jul; 5(7):e148. PubMed ID: 18613745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can highly active antiretroviral therapy reduce the spread of HIV?: A study in a township of South Africa.
    Auvert B; Males S; Puren A; Taljaard D; Caraël M; Williams B
    J Acquir Immune Defic Syndr; 2004 May; 36(1):613-21. PubMed ID: 15097305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Harmful alcohol consumption and patterns of substance use in HIV-infected patients receiving antiretrovirals (ANRS-EN12-VESPA Study): relevance for clinical management and intervention.
    Michel L; Carrieri MP; Fugon L; Roux P; Aubin HJ; Lert F; Obadia Y; Spire B;
    AIDS Care; 2010 Sep; 22(9):1136-45. PubMed ID: 20824566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.
    Mocroft A; Madge S; Johnson AM; Lazzarin A; Clumeck N; Goebel FD; Viard JP; Gatell J; Blaxhult A; Lundgren JD
    J Acquir Immune Defic Syndr; 1999 Dec; 22(4):369-78. PubMed ID: 10634199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparing for highly active antiretroviral therapy rollout in rural South Africa: an assessment using the information, motivation, and behavioral skills model.
    Simon MD; Altice FL; Moll AP; Shange M; Friedland GH
    AIDS Care; 2010 Apr; 22(4):462-74. PubMed ID: 20204909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hospitalization in HIV in Chicago.
    Sherer R; Pulvirenti J; Stieglitz K; Narra J; Jasek J; Green L; Moore B; Shott S; Cohen M
    J Int Assoc Physicians AIDS Care (Chic); 2002; 1(1):26-33. PubMed ID: 12942666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.